MediWound to Report First Quarter 2025 Financial Results
Rhea-AI Summary
MediWound Ltd. (NASDAQ: MDWD), a leader in enzymatic therapeutics for tissue repair, has scheduled its first quarter 2025 financial results announcement for Wednesday, May 21, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time following the results release.
Investors can access the call through various channels including toll-free (1-844-676-8833), Israel (1-80-921-2373), and international (1-412-634-6869) numbers. A webcast replay will be available in the Investors section of MediWound's website after the call.
Positive
- None.
Negative
- None.
News Market Reaction – MDWD
In the trading session that priced this news, MDWD gained 2.67%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time
YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 21, 2025.
Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates.
Dial-in and call details are as follows:
| Conference Call & Webcast Details | |
| Toll-Free: | 1-844-676-8833 |
| Israel: | 1-80-921-2373 |
| International: | 1-412-634-6869 |
| Webcast: | Click HERE |
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.
For more information, visit www.mediwound.com and follow us on LinkedIn.
| MediWound Contacts: | |
| Hani Luxenburg | Daniel Ferry |
| Chief Financial Officer | Managing Director |
| MediWound Ltd. | LifeSci Advisors, LLC |
| ir@mediwound.com | daniel@lifesciadvisors.com |
| Media Contact: | |
| Ellie Hanson | |
| FINN Partners for MediWound | |
| ellie.hanson@finnpartners.com | |
| +1-929-588-2008 | |
